Key clinical point: The use of the NFS and FIB-4 score may reduce the need for liver biopsy by identifying NAFLD patients at higher risk of having advanced liver fibrosis.
Major finding: NFS greater than 0.676 was significantly associated with CVEs after adjustment for comorbidities (HR, 2.29), and FIB-4 score greater than 2.67 predicted incident CVEs (HR, 4.57).
Study details: A prospective observational study of 898 patients.
Disclosures: The authors reported having no disclosures.
Baratta F et al. Clin Gastroenterol Hepatol. doi: 10.1016/j.cgh.2019.12.026.